From serving at Ground Zero after September 11th to advancing patient-centered oncology care at Daiichi Sankyo, John Ruggiero shares how resilience, compassion, and purpose shaped his journey into the pharmaceutical industry. As Executive Director, U.S. Medical Affairs, HEOR, he reflects on cancer research, patient empowerment, and the culture that keeps him inspired.
Daiichi Sankyo honors its Japanese heritage and connection to the cherry blossom trees in Washington, D.C. as a perennial sponsor of the National Cherry Blossom Festival. Learn about the special link and watch a video capturing the joy felt by Daiichi Sankyo employees participating in the festival parade.
Translating facts into memorable stories is a powerful craft. Discover how Daiichi Sankyo communications leader Kim Wix inspires action via storytelling.
Informed patients are empowered patients. Which is why helping people with cancer understand their disease, as well as how available treatment options might work for them, is a critical focus of our patient advocacy efforts.
Business development is the craft of making connections. Whether with other companies or within our organization, we need to build those bonds that allow us to be successful.
Cancer research and development is a dynamic and ever-evolving field. One significant area of focus is the role of HER2.
The Galien Foundation has recognized Daiichi Sankyo’s HER2 directed antibody drug conjugate (ADC) with the prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.